Exploiting knowledge on Leishmania drug resistance to support the quest for new drugs

Aya Hefnawy; Maya Berg; Jean-Claude Dujardin; Geraldine De Muylder

doi:10.1016/j.pt.2016.11.003

Exploiting knowledge on Leishmania drug resistance to support the quest for new drugs

Aya Hefnawy, Maya Berg, Jean-Claude Dujardin, Geraldine De Muylder

Moleculaire Parasitologie

Onderzoeksoutput: Bijdrage aan tijdschrift › A1: Web of Science-artikel

Uittreksel

New drugs are needed to control leishmaniasis and efforts are currently ongoing to counter the neglect of this disease. We discuss here the utility and the impact of associating drug resistance (DR) studies to drug discovery pipelines. We use as paradigm currently used drugs, antimonials and miltefosine, and complement our reflection by interviewing three experts in the field. We suggest DR studies to be involved at two different stages of drug development: (i) the efficiency of novel compounds should be confirmed on sets of strains including recent clinical isolates with DR; (ii) experimental DR should be generated to promising compounds at an early stage of their development, to further optimize them and monitor clinical trials.

Taal	Engels
Tijdschrift	Trends In Parasitology
Volume	33
Exemplaarnummer	3
Pagina's (van-tot)	162-174
Aantal pagina's	13
ISSN	1471-4922
DOI's	https://doi.org/10.1016/j.pt.2016.11.003
Status	Gepubliceerd - 2017

Toegang verkrijgen tot document

10.1016/j.pt.2016.11.003

Vingerafdruk Bekijk de onderzoeksthema's van 'Exploiting knowledge on <em>Leishmania</em> drug resistance to support the quest for new drugs'. Samen vormen ze een unieke vingerafdruk.

Dit citeren

@article{c892240a9a374b71818c1983025b1bf7,

title = "Exploiting knowledge on Leishmania drug resistance to support the quest for new drugs",

abstract = "New drugs are needed to control leishmaniasis and efforts are currently ongoing to counter the neglect of this disease. We discuss here the utility and the impact of associating drug resistance (DR) studies to drug discovery pipelines. We use as paradigm currently used drugs, antimonials and miltefosine, and complement our reflection by interviewing three experts in the field. We suggest DR studies to be involved at two different stages of drug development: (i) the efficiency of novel compounds should be confirmed on sets of strains including recent clinical isolates with DR; (ii) experimental DR should be generated to promising compounds at an early stage of their development, to further optimize them and monitor clinical trials.",

keywords = "AQUAGLYCEROPORIN AQP1 GENE, ABC-TRANSPORTER MRPA, VISCERAL LEISHMANIASIS, ANTIMONY-RESISTANT, INTRACELLULAR AMASTIGOTES, DONOVANI PROMASTIGOTES, GLUCANTIME-RESISTANT, TREATMENT FAILURE, L. DONOVANI, MILTEFOSINE",

author = "Aya Hefnawy and Maya Berg and Jean-Claude Dujardin and {De Muylder}, Geraldine",

note = "NPP",

year = "2017",

doi = "10.1016/j.pt.2016.11.003",

language = "English",

volume = "33",

pages = "162--174",

journal = "Trends In Parasitology",

issn = "1471-4922",

publisher = "Elsevier Science",

number = "3",

}

TY - JOUR

T1 - Exploiting knowledge on Leishmania drug resistance to support the quest for new drugs

AU - Hefnawy, Aya

AU - Berg, Maya

AU - Dujardin, Jean-Claude

AU - De Muylder, Geraldine

N1 - NPP

PY - 2017

Y1 - 2017

N2 - New drugs are needed to control leishmaniasis and efforts are currently ongoing to counter the neglect of this disease. We discuss here the utility and the impact of associating drug resistance (DR) studies to drug discovery pipelines. We use as paradigm currently used drugs, antimonials and miltefosine, and complement our reflection by interviewing three experts in the field. We suggest DR studies to be involved at two different stages of drug development: (i) the efficiency of novel compounds should be confirmed on sets of strains including recent clinical isolates with DR; (ii) experimental DR should be generated to promising compounds at an early stage of their development, to further optimize them and monitor clinical trials.

AB - New drugs are needed to control leishmaniasis and efforts are currently ongoing to counter the neglect of this disease. We discuss here the utility and the impact of associating drug resistance (DR) studies to drug discovery pipelines. We use as paradigm currently used drugs, antimonials and miltefosine, and complement our reflection by interviewing three experts in the field. We suggest DR studies to be involved at two different stages of drug development: (i) the efficiency of novel compounds should be confirmed on sets of strains including recent clinical isolates with DR; (ii) experimental DR should be generated to promising compounds at an early stage of their development, to further optimize them and monitor clinical trials.

KW - AQUAGLYCEROPORIN AQP1 GENE

KW - ABC-TRANSPORTER MRPA

KW - VISCERAL LEISHMANIASIS

KW - ANTIMONY-RESISTANT

KW - INTRACELLULAR AMASTIGOTES

KW - DONOVANI PROMASTIGOTES

KW - GLUCANTIME-RESISTANT

KW - TREATMENT FAILURE

KW - L. DONOVANI

KW - MILTEFOSINE

U2 - 10.1016/j.pt.2016.11.003

DO - 10.1016/j.pt.2016.11.003

M3 - A1: Web of Science-article

C2 - 27993477

VL - 33

SP - 162

EP - 174

JO - Trends In Parasitology

JF - Trends In Parasitology

SN - 1471-4922

IS - 3

ER -